Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter), a subsidiary of Abbisko Cayman Limited (Stock Code: 2256.HK), today announced that it has entered into a worldwide collaboration and exclusive licensing agreement (the "Agreement") with Eli Lilly and Company ("Lilly") for the further discovery, development and potential commercialization of novel molecules against an undisclosed target for cardiometabolic disea...
Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter), a subsidiary of Abbisko Cayman Limited (Stock Code: 2256.HK), today announced that it has entered into a worldwide collaboration and exclusive licensing agreement (the "Agreement") with Eli Lilly and Company ("Lilly") for the further discovery, development and potential commercialization of novel molecules against an undisclosed target for cardiometabolic diseases with critical unmet medical needs.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.